Skip to main content

Michaela Ann Dinan

Adjunct Associate Professor in Population Health Sciences
Population Health Sciences
Duke Box 104023, Durham, NC 27710
60 College St, PO Box 208034, New Haven, CT 06520

Overview


Dr. Dinan is a health services researcher by training and she specializes in using econometric and epidemiologic methodologies to analyze complex datasets. Specifically, Dr. Dinan's research involves issues related to advances in cancer care technologies, such as emerging treatments and diagnostics, and how these advances in technologies impact different cancer outcomes and experiences such as access, quality of care, cost of care, and health disparities.

Dr. Dinan has led studies funded by the National Institutes of Health, the American Cancer Society, and the Agency for Healthcare Research and Quality. She is currently leading an NCI-funded R01 study examining multi-level factors that contribute to disparities in access and adherence to oral anticancer agents for patients with kidney cancer. Dr. Dinan is also leading a study funded by the ACS to develop and validate risk prediction algorithms to inform efficient and high-quality care for long-term cancer survivors.

Areas of expertise: Health Economics, Health Policy, and Health Services Research

Current Appointments & Affiliations


Adjunct Associate Professor in Population Health Sciences · 2023 - Present Population Health Sciences, Basic Science Departments

In the News


Published August 27, 2015
Breast Cancer Risk Score Impacts Use of Chemotherapy

View All News

Recent Publications


Biomarker-Specific Survival and Medication Cost for Patients With Non-Small Cell Lung Cancer.

Journal Article JAMA Netw Open · June 2, 2025 IMPORTANCE: Targeted therapies and immunotherapies prolong survival but are associated with high costs for patients with advanced non-small cell lung cancer (aNSCLC). To date, little is known about survival and medication cost by biomarker status in the US ... Full text Link to item Cite

Off-Label Use of First-Line Immunotherapy for Metastatic Renal Cell Carcinoma.

Journal Article Clin Genitourin Cancer · June 2025 INTRODUCTION: Immune checkpoint inhibitors (ICI) were approved by the Food and Drug Administration (FDA) for patients with metastatic renal cell carcinoma (mRCC) in the second- line setting in 2015 and the first-line (1L) in 2018. Little is known about 1 L ... Full text Link to item Cite
View All Publications

Recent Grants


Disparities in the Use of Oral Anticancer Agents in Kidney Cancer

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2020

Bladder Cancer in Older Adults - Treatment and Outcomes

ResearchCo Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2016 - 2017

View All Grants

Education, Training & Certifications


University of Virginia · 2003 B.S.